Alfred Clinical Trials

Alfred Health has more than 700 open trials across 20 clinical disciplines, our clinical trial portfolio is one of the largest in the country.

Clear filter
604 clinical trials found
Clinical trials

TRANSFORM-2

A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis (TRANSFORM-2) (NCT04468984)

No longer recruiting

DeLLphi-304

A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy (DeLLphi-304) (NCT05740566)

No longer recruiting

KarMMa-9

A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants with Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9) (NCT06045806)

Currently recruiting

EFC15951

A randomized, Phase 3, open label study evaluating subcutaneous versus intravenous administration of isatuximab in combination with pomalidomide and dexamethasone in adult patients with relapsed and/or refractory multiple myeloma (RRMM) (NCT05405166)

Currently recruiting

SGNB6A-002 [Be6A Lung-01]

A randomized, phase 3, open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer (NCT06012435)

No longer recruiting

SPG302-SCZ-201

A Randomized, Placebo-controlled, Double-blind Phase 2 Study to Assess the Efficacy, Safety, Tolerability, and Pharmacodynamics of SPG302 in adult participants diagnosed with Schizophrenia (NCT06442462)

Currently recruiting

POLARIS-3

A Single-Arm Registrational Phase III Study of Olverembatinib in the Treatment of Patients with SDH-Deficient Gastrointestinal Stromal Tumor [POLARIS-3] (NCT06640361)

Currently recruiting

ADVANCE-outcomes

A StuDy eVAluatiNg the EffiCacy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients (ADVANCE-outcomes) (NCT03626688)

Currently recruiting

ADVANCE-extension

A StuDy EVAluatiNg the Long-Term EffiCacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION (ADVANCE-extension) (NCT03683186)

Currently recruiting

ACTIVATE AVF

A study of the safety and feasibility of the Vessel Restoration System for AVF to promote the physiologic and functional maturation of upperextremity autologous End-to-Side Arteriovenous Fistulas (AVF) in Patients with Chronic Kidney Disease: ACTIVATE AVF (NCT05462223)

Recently completed/closed

BJT-008-001

A Study to Evaluate Cavrotolimod in Subjects with Chronic Hepatitis B Virus [HBV] Infection (ACTRN12624000809538)

Currently recruiting

AT02-001

A Three-part, Phase 1, Single-ascending, and Multiple-ascending Dose Escalation Study in Healthy Volunteers and Subjects with Systemic Amlyoidosis to Assess the Safety Tolerability, and Pharmacokinetics of AT-02 (NCT05521022)

Currently recruiting

Longevity LBT3627-101

A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Subjects and in Subjects with Parkinson’s disease (NCT06466525)

Currently recruiting

LWH RCT

A Type II Hybrid Effectiveness-Implementation, Randomised Control Trial of Left Write Hook for Adult Survivors of Child Sexual Abuse (ACTRN12624000862549)

Currently recruiting

ENVISION

ABT-CIP-10487 ENVISION Trial - Evaluation of the Navitor Transcatheter Heart Valve in Low and Intermediate Risk Patients (NCT05932615)

Coming soon

FLAP ATTACK

Accelerated Flap Coverage Versus Standard Timing in the Treatment of Severe Lower Extremity Musculoskeletal Injuries (NCT06293469)

Currently recruiting

ACT17967

ACT17967 - A phase 2, randomized, double-blind, placebo-controlled, parallel group, proof-of-concept study assessing the efficacy and safety of amlitelimab in adult participants with moderate to severe hidradenitis suppurativa (NCT06118099)

Currently recruiting

BCG+MM

Adding mitomycin C to BCG as adjuvant intravesical therapy for high risk, non–muscle invasive bladder cancer: A randomised phase 3 trial (ACTRN12613000513718)

Currently recruiting

INTERCEPT-MGB453

AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial (ACTRN12621000439842)

Currently recruiting

INTERVENE

An ALLG Phase 2 study to Investigate Novel Triplets to Extend Remission with VENetoclax in Elderly (INTERVENE) Acute Myeloid Leukaemia (ACTRN12619001655134)

Currently recruiting
15 16 17 18 19